药物涂层球囊在直接经皮冠状动脉介入治疗中的临床应用研究进展

Clinical research progress of drug coated balloon in primary percutaneous coronary intervention

药物洗脱支架(DES)植入是目前国内外指南推荐直接经皮冠状动脉介入治疗(PPCI)首选策略。DES植入损害血管自主舒缩且伴随支架血栓形成和支架内再狭窄风险,促使“介入无植入理念”提出。药物涂层球囊(DCB)通过与血管内皮接触可将药物均匀释放于血管内膜,有效抑制血管内膜过度增生,达到改善心肌血流灌注目的,实现介入无植入。目前少量研究报道了DCB在直接经皮冠状动脉介入治疗中的临床疗效,文章就相关临床研究进展做一综述。

Drug eluting stent(DES)are widely recommended for primary percutaneous coronary intervention(PCI).However,DES implantation can affect vascular autoregulatory function and is linked to risks of stent thrombosis and in-stent restenosis.This has led to the proposal of the"no implant intervention"concept.Drug coated balloon(DCB)release medication uniformly upon contact with the vascular endothelium,effectively inhibiting excessive intimal hyperplasia and improving myocardial perfusion without the need for permanent implants.While limited studies have reported on the clinical efficacy of DCB in Primary PCI(PPCI),this article provides a review of the relevant clinical research progress.